Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152203 · ClinicalTrials.gov registry record · Phase 1
Bendamustine and Bevacizumab for Advanced Cancers
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT01152203: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01152203 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01152203, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01152203
The ClinicalTrials.gov registry entry for NCT01152203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01152203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01152203 about?
NCT01152203 is a clinical study titled "Bendamustine and Bevacizumab for Advanced Cancers". The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.
What is the current status of trial NCT01152203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2010-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01152203?
The interventions under investigation include: Bevacizumab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01152203?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.